中國生物製藥(01177.HK)與禮新醫藥簽署股權投資及戰略合作協議
格隆匯11月20日丨中國生物製藥(01177.HK)發佈公吿，集團與禮新醫藥科技(上海)有限公司(“禮新醫藥”)簽署股權投資及戰略合作協議。據此，集團以自籌資金入股禮新醫藥，並就LM-108及未來潛在的多個創新雙特異性抗體或抗體偶聯藥物(ADC)在中國大陸地區達成戰略合作。
禮新醫藥於2024年10月18日宣佈完成3億元人民幣C1輪融資，募集資金用於加快推進臨牀管線藥物開發和創新平台建設。根據增資認購協議，集團作為本輪融資領投方，向禮新醫藥支付1.42億元人民幣，取得本次交易後禮新醫藥4.91%的股權。
集團與禮新醫藥就LM-108在中國大陸地區達成戰略合作協議。另外，集團有權選擇禮新醫藥在研管線中多個雙特異性抗體或ADC創新藥物進行合作，具體條款另行約定。LM-108是禮新醫藥基於其獨家多次跨膜蛋白抗體發現平台，自主研發的靶向CCR8的單克隆抗體。CCR8特異性表達於腫瘤微環境中的調節性T細胞(Treg)，其只在腫瘤浸潤的Treg中高表達，而在外周血中基本不表達。目前已在乳腺癌、肺癌、腸癌、頭頸癌的Treg中均觀察到CCR8的特異性表達。LM-108在不影響外周Treg的情況下，特異性清除腫瘤浸潤Treg，增強對腫瘤細胞的免疫殺傷效果。
LM-108目前處於II期臨牀階段，其開發進度在中國同靶點項目中排名第一、全球排名前三。早期探索臨牀研究數據顯示，LM-108在多種實體瘤治療中均展現良好的安全性和療效，有望為晚期腫瘤患者提供更好的治療選擇。
公吿表示，腫瘤領域是集團創新發展的重點治療領域之一，經過多年深耕，已有多款重磅產品獲批上市，亦有多個創新藥項目位於臨牀開發階段。禮新醫藥是一家聚焦腫瘤領域創新藥研發的公司，擁有單抗篩選平台、雙抗技術平台和ADC藥物開發技術平台，並建立了多個差異化的創新藥研發管線。集團在生物醫藥產業積累了豐富的臨牀開發及商業化優勢和資源，通過本次股權投資及戰略合作，將進一步豐富完善集團在腫瘤領域的管線佈局，集團也將為禮新醫藥的創新藥管線開發和商業化提供全面支持，加速推動產品上市，造福更多腫瘤患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
